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Abstract
Background: The infection of a participant with norovirus during the adaptive
study of interleukin-2 dose on regulatory T cells in type 1 diabetes (DILT1D)
allowed a detailed insight into the cellular and cytokine immune responses to
this prevalent gastrointestinal pathogen.
Methods: Serial blood, serum and peripheral blood mononuclear cell (PBMC) 
samples were collected pre-, and post-development of the infection. To
differentiate between the immune response to norovirus and to control for the
administration of a single dose of aldesleukin (recombinant interleukin-2, rIL-2)
alone, samples from five non-infected participants administered similar doses
were analysed in parallel.
Results: Norovirus infection was self-limited and resolved within 24 hours, with
the subsequent development of anti-norovirus antibodies. Serum pro- and
anti-inflammatory cytokine levels, including IL-10, peaked during the
symptomatic period of infection, coincident with increased frequencies of
monocytes and neutrophils. At the same time, the frequency of regulatory CD4
T cell (Treg), effector T cell (Teff) CD4  and CD8  subsets were dynamically
reduced, rebounding to baseline levels or above at the next sampling point 24
hours later.  NK cells and NKT cells transiently increased CD69 expression and
classical monocytes expressed increased levels of CD40, HLA-DR and
SIGLEC-1, biomarkers of an interferon response. We also observed activation
and mobilisation of Teffs, where increased frequencies of CD69  and Ki-67
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 and mobilisation of Teffs, where increased frequencies of CD69  and Ki-67
effector memory Teffs were followed by the emergence of memory CD8  Teff
expressing the mucosal tissue homing markers CD103 and β7 integrin. Treg
responses were coincident with the innate cell, Teff and cytokine response.
Key Treg molecules FOXP3, CTLA-4, and CD25 were upregulated following
infection, alongside an increase in frequency of Tregs with the capacity to
home to tissues.
Conclusions: The results illustrate the innate, adaptive and counter-regulatory 
immune responses to norovirus infection. Low-dose IL-2 administration induces
many of the Treg responses observed during infection.
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Introduction
We conducted an interleukin-2 (IL-2; aldesleukin [Proleukin]) 
dose-finding, mechanistic trial, “Adaptive study of IL-2 dose on 
regulatory T cells in type 1 diabetes” (DILT1D), in 40 participants 
with type 1 diabetes (T1D), as a first step towards treatment and 
prevention of T1D by enhancing Treg functions1,2. Adverse events 
were recorded throughout the trial and one participant developed 
an acute gastrointestinal infection, confirmed as norovirus, in the 
period of daily sampling post-IL-2 injection. Noroviruses cause 
approximately 1 in 5 of all diarrhoea cases3 and are a leading cause 
of acute viral gastroenteritis worldwide. In immunocompetent 
individuals, norovirus infection is contained within the gastroin-
testinal tract4 and induces little pathology to the mucosal tissues5, 
although complications such as necrotising enterocolitis, post-
infectious irritable bowel syndrome or exacerbation of inflamma-
tory bowel disease may occur. The immune response to norovirus 
infection is only partly understood, largely due until recently to the 
lack of suitable animal models and difficulty in growing human 
norovirus in cell culture. Nevertheless, it is becoming clear that 
autophagy, innate and adaptive immune responses are involved in 
the control of murine norovirus infection6. A functional immune 
system is imperative for acute control of norovirus infection in 
humans7, and pre-existing anti-norovirus IgA antibody titers neg-
atively correlate with severity of symptoms in human challenge 
studies8. Mouse models and human studies also suggest a signifi-
cant role for type-I, type-II and type-III interferon responses in 
control of norovirus infection9–11.
The longitudinal design of the mechanistic trial, including frequent 
blood sampling and deep phenotyping protocols before and after 
IL-2 treatment, allowed thorough investigation of cellular responses 
and immune phenotypes associated with norovirus infection. Sam-
pling the blood did not allow direct investigation of the mucosal 
immune response to norovirus infection. Nevertheless, the systemic 
nature of the response provided insight into the coincident effector 
cell activation and counter-regulatory immune response induced by 
norovirus infection.
Methods
Study design
The adaptive study of IL-2 dose on Tregs in T1D (DILT1D) was 
a 60-day duration, single center, single dose non-randomised, 
open label, adaptive dose-finding trial that was conducted at the 
National Institute for Health Research Cambridge Biomedical 
Centre, Addenbrooke’s Hospital, Cambridge, United Kingdom1. 
Potential participants were eligible for the study if they had a dis-
ease duration of less than 2 years, were positive for at least one 
autoantibody (anti-islet cell, anti-IA2, anti-ZnT8 and anti-GAD) 
and were between 18 – 50 years of age. The study had 12 visits: 
after a screening visit, the IL-2 dose (aldesleukin, [Proleukin], 
Novartis Pharmaceuticals Ltd UK) was subcutaneously admin-
istered on day 0, and the participants were then followed up 
and blood was taken at 90 minutes and days 1, 2, 3, 4, 7, 9, 
14, 21 and 60 after administration of drug. Participants were 
clinically assessed before dosing and monitored for adverse 
events (AE) including infections at each subsequent time point. 
Samples of blood taken at each visit were subject to polychro-
matic flow cytometric immunophenotyping, serum samples were 
measured for biomarkers of immune activation and peripheral 
blood mononuclear cell (PBMC) samples were isolated and cry-
opreserved. The trial enrolled forty participants, and they were 
divided into five dose groups. In the 0.385-0.610 × 106 IU/m2 group, 
a single participant (IL-2 dose: 0.433 × 106 IU/m2) incidentally 
developed a norovirus infection 30 hours into the trial. The pre-
treatment and longitudinally collected samples from this participant 
and five other participants that received similar doses (dose range 
0.408 – 0.445 × 106 IU/m2), were analysed to characterise the 
immune response to the pathogen and compare it to low dose 
IL-2 treatment alone. The study was sponsored by the University 
of Cambridge and Cambridge University Hospitals NHS Founda-
tion Trust. Ethical approval was granted by the Health Research 
Authority, National Research Ethics Service, England (approval 
number: 13/EE/0020) and was registered in the ISRCTN Registry 
(ISRCTN27852285) and at ClinicalTrials.gov (NCT01827735). 
The detailed description of the protocol, design and rationale of 
DILT1D was published prior to analysis of this data2.
Cytokine and soluble receptor measurement
Serum or plasma cytokines were measured using electrochemi-
luminescence assays (Meso Scale Discovery [MSD], Rockville, 
Maryland, USA). IL-6 (plasma diluted 1:10) and IL-2 (plasma 
diluted 1:3) were measured at MSD, in quadruplicate, by the high-
sensitivity S-PLEX assay. The IL-2 assay (limit of quantitation 
2 fg/ml) fg/ml values were converted to IU/ml as detailed1. 
Serum IL-12p70, IL-10 and TNF-α levels were measured using a 
multiplex assay using the V-PLEX proinflammatory panel 1 
(human) kit (MSD). Samples were diluted 1:3 in proprietary 
buffer (MSD) and measured in duplicate. Plasma IFN-γ, IP-10 and 
CRP levels were measured in a single-plex assay using V-PLEX 
human IFN-γ, IP-10 (CXCL10) and CRP V-PLEX human kits, 
respectively (MSD). Samples were diluted 1:2, 1:4 or 1:1000, 
respectively and measured in duplicate. Data were acquired using 
a SECTOR S 6000 plate reader (MSD). 
Soluble CD25 (sCD25) was measured in duplicate in plasma 
(diluted 1:20) using an in-house sandwich immunoassay, as 
described in Downes et al., 201412. Circulating soluble SIGLEC-1 
(sSIGLEC-1) concentrations were measured in duplicate in plasma 
samples (diluted 1:10) using a non-isotopic time-resolved fluores-
cence ELISA assay based on the dissociation-enhanced lanthanide 
fluorescent immunoassay technology (DELFIA; PerkinElmer). 
Test plasma samples were measured on 96-well MaxiSorp 
microtiter plates (Nunc), and coated with 1 μg/ml monoclonal 
anti-human SIGLEC-1 antibody (clone HSn7D2; ABCAM). 
Detection was performed using a biotinylated sheep polyclonal 
anti-SIGLEC-1 (R&D Systems) diluted to a final concentration 
of 200 ng/ml in PBS + 10% FBS and a Europium-Streptavidin 
detection solution (PerkinElmer), diluted in standard DELFIA 
buffer. Quantification of test samples was obtained by fitting 
the readings to a human recombinant human SIGLEC-1 (R&D 
Systems) serial dilution standard curve plated in quadruplicate on 
each plate.
Norovirus, vesivirus and hepatitis E virus antibody detection
Anti-norovirus, -vesivirus and -hepatitis E virus (HEV) antibody 
levels were measured by ELISA. Test serum samples were diluted 
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1:100 in PBS + 0.05% Tween 20 and were measured in duplicate 
on 96-well MaxiSorp microtiter plates (Nunc). They were coated 
overnight at 4°C with either 25 ng of norovirus (GII.4 Dijon) virus-
like particle (VLP) (a kind gift from Alexis de Rougemont, Dijon, 
France), vesivirus (2117) VLP or HEV VLP (both generated in the 
Goodfellow laboratory) in 0.05 M carbonate/bicarbonate buffer 
(pH 9.6). Anti-viral antibodies were detected using horseradish 
peroxidase (HRP)-conjugated anti-human IgG antibody (Sigma 
Aldrich) diluted 1:10,000 in 5% milk PBS–Tween 20. Bound 
antibody was detected with tetramethylbenidine (TMB, Sigma 
Aldrich), the reaction was stopped with 1N H2SO4 and the optical 
density (OD) was read at 450 nm (Spectromax M2 plate reader, 
Molecular Devices).
Norovirus RNA detection
RNA purified from 0.5 × 106 PBMCs resuspended in RLT buffer 
(RNeasy micro kit, Qiagen, Germany) from each timepoint was 
tested using real-time qRT-PCR following the same protocol as in 
Kageyama et al.13 using the GII primers/probes, as stated.
Whole blood counts and flow cytometric analysis
Whole blood counts were carried out at the Pathology Partnership, 
Addenbrooke’s Hospital, Cambridge.
Clinical FACS:
The FACS assays used to measure T, B and NK cell counts and 
total Treg frequency was carried out according to good laboratory 
practice at the Clinical Immunology Laboratory, Department of 
Immunology, Addenbrooke’s Hospital, Cambridge, as described1. 
Whole blood surface staining. Venous blood was collected in 
lithium heparin coated tubes (BD Biosciences). 100 μl of blood 
was stained with antibodies and brilliant violet staining buffer 
(Biolegend, San Diego, USA) for 40 minutes at room tempera-
ture. Stained blood samples were vortexed and the red blood cells 
lysed (FACS lysing solution, BD). The stained cells were resus-
pended in PBS (Life technologies, Paisley, UK), supplemented with 
0.2 % BSA (Sigma-Aldrich, Gillingham, UK). See Supplementary 
Table 1 (panels 1–4) to see the panels used for surface staining.
Intracellular/Intranuclear staining. 150 μl of surface-stained 
blood was fixed and cells permeabilised using intranuclear stain-
ing Fixation/Permeabilization Buffer (Affymetrix eBioscience, 
Hatfield, UK). Cells were then stained in permeabilisation 
buffer (eBiosciences) as previously published14 (see panel 5 in 
Supplementary Table 1).
Cryopreserved PBMC staining. PBMC aliquots were thawed 
at 37oC, transferred to a new tube and reconstituted with ice 
cold RPMI-1640 (Life Technologies) supplemented with 10% 
FBS in a dropwise fashion. PBMCs were washed twice in RPMI-
1640 + 10% FBS. PBMCs were stained at room temperature for 
40 minutes (see panels 7–9 in Supplementary Table 1). Cells were 
then incubated with Fixable Viability Dye eFluor780, (eBioscience) 
and fixed (FACS lysing solution, BD) prior to data acquisition.
Phosphorylation of STAT5a staining. Whole blood pSTAT5a 
staining was carried out as previously described15 (see panel 6 in 
Supplementary Table 1).
All data were acquired on a Fortessa flow cytometer (BD) 
using FacsDiva software v6.2 (BD) and analysed using FlowJo 
software v9.6 (FLOWJO, LLC, Oregon, USA). 
Results
Clinical course
The index case in our study, presented with T1D aged 18, eight 
months prior to participation in DILT1D. At screening there was 
evidence of beta-cell autoimmunity with elevated titers of anti-
GAD65 (92 U/ml [NR:1-5]) and anti-IA-2 (16 U/ml [NR:<7.5]), 
with preservation of some endogenous insulin production (random 
C-peptide 392 pmol/l [NR:174-960]), normal biochemical and 
hematological indices and no evidence of blood borne viruses. 
As detailed1, prior to administration of IL-2, clinical history, 
examination and laboratory investigations were largely normal. 
The participant received a single dose of IL-2 subcutaneously 
(0.433 × 106 IU/m2) and had a normal clinical assessment 
24 hours post-drug administration. Six hours later the partici-
pant first developed mild abdominal pain and nausea that per-
sisted without metabolic deterioration (capillary blood glucose 
– 6.6 mmol). Forty-eight hours after administration, the partici-
pant, reviewed at home by the clinical trial team, reported ongo-
ing abdominal discomfort and nausea but with good oral intake 
and adequate glucose control. That evening he deteriorated with 
progressive nausea, vomiting, sweats and limited oral intake 
accompanied by elevation in capillary blood glucose (> 25 mmol/l) 
with a concomitant rise in ketone levels. On the advice of the study 
team, he consumed 100 ml sugar-free fluid every 30 minutes to 
ensure adequate hydration and self-administered 10% of his total 
daily insulin requirement as a single subcutaneous dose of quick 
acting insulin to circumvent the onset of ketoacidosis. Within 
two hours of these interventions, capillary blood ketones were 
undetectable (< 0.3 mmol/l) and the participant was tolerating 
oral fluids, and a clinical diagnosis of norovirus infection was 
made. Twelve hours later, 72 hours following drug administration, 
symptoms and hyperglycemia were completely resolved.
Induction of anti-norovirus antibody response
To confirm the diagnosis, analysis of the serum for anti- 
norovirus antibodies was performed, showing an induction of anti-
GII.4 IgG antibody titers post-infection (Figure 1A)1. We noted 
the low/undetectable level of pre-existing anti-norovirus antibod-
ies, reflecting the blood group secretor status of the participant16. 
The trial participant was homozygous for the 428G>A null muta-
tion (rs601338 genotype AA) in FUT2 and therefore does not 
express a functional α(1,2) fucosyltransferase enzyme that 
renders individuals largely, but not always, resistant to infec-
tion with GII.4 noroviruses17. IL-2 treatment did not alter anti- 
GII.4 IgG titers in uninfected trial participants (n = 5) who had 
received a similar dose (range = 0.408 – 0.445 × 106 IU IL-2/m2) 
(Figure 1A). Molecular testing for the GII genogroup norovi-
rus RNA in PBMCs was negative at all visits in this participant, 
consistent with studies of immunocompetent adults in whom 
it is rare to detect norovirus RNA during infection4,5 (Figures S1A 
and S1B). The trial protocol did not allow sampling of vomitus or 
fecal samples, precluding the direct demonstration of norovirus 
RNA in the participant. To exclude the possibility that the anti-
GII.4 titers represented a broad non-specific anti-viral antibody 
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Figure 1. Specific increase in anti-norovirus GII.4 antibodies in the trial participant with gastrointestinal symptoms. (A) Anti-norovirus 
GII.4 Dijon virus-like particles (VLP) serum antibody titres at day 0 (red filled circles), day 14 (filled black squares) and day 60 (filled blue 
circles) post-IL-2 dosing in six participants (5 dose-matched uninfected participants) and a participant with gastrointestinal symptoms 
receiving 0.408 – 0.445 × 106 IU IL-2/m2. (B) Anti-vesivirus and hepatitis E virus (HEV) titres were assessed pre-IL-2 (filled red circle +/- SD) 
and day 60 post-IL-2 administration (filled blue circle +/- SD) in the infected participant.
response we tested serum against hepatitis E virus and vesivirus 
antigen and observed that serum IgG levels to both antigens were 
unchanged throughout the trial in the norovirus-infected participant 
(Figure 1B).
Cytokine and inflammatory marker responses
The intensive longitudinal sampling in the DILT1D proto-
col allowed for measurement of serum cytokines/inflammatory 
markers pre- and post-norovirus infection within the affected 
participant. The inflammatory responses to the pathogen in the 
affected participant could also be compared to five control partici-
pants from the same dose group, enabling a comparison between 
antiviral and IL-2 drug responses. A primary increase in IL-2 
levels (2.17–6.74 IU/ml) was observed in all participants at the 
90 minute sampling point post drug administration, concordant 
with the systemic distribution of the drug (Figure 2A), whereas a 
secondary peak of IL-2 (1.64 IU/ml) at day 2 was only detected 
in the infected participant. Infection induced an early increase in 
IL-12p70 levels (0–1.3 pg/ml) (Figure 2B) and increases above 
baseline in TNF-α (102%) (Figure 2C), IL-6 (382%) (Figure 2D) 
and IL-10 (166%) (Figure 2E) levels at day 2. Although serum 
IFN-γ (73.6%), IP-10 (21.72%), and CRP (67.3%) were increased 
above baseline levels by the drug (day 1), the increases in IFN-γ 
(Figure 2F), IP-10 (Figure 2G) were 26- and 14-fold higher, 
respectively, in the norovirus-infected participant at day 2 of the 
trial. A 40-fold increase in CRP levels was induced by norovi-
rus infection compared to drug alone (Figure 2H). Notably, the 
peak of the CRP response was observed 24 h after the peak of 
proinflammatory cytokines detected in the serum. SIGLEC-1 
expression on monocytes has been previously proposed as an 
interferon-induced biomarker of infection, vaccine response or 
disease activity18–20. IL-2 injection induced a small (18%) increase 
in sSIGLEC-1 levels above baseline. However, in line with the 
increased production of proinflammatory cytokines, norovirus 
infection induced a profound and sustained sSIGLEC-1 release 
(day 7 maximum, 83% increase, day 14 return to baseline) 
(Figure 2I).
Innate immune cell responses to norovirus infection
Norovirus infection is generally considered to be limited to the 
gastrointestinal tract, with little evidence of systemic dissemina-
tion of the virus in immunocompetent individuals5. Norovirus 
RNA was not detected in circulating PBMCs from the infected 
participant (Figure S1). Given the rapid proinflammatory cytokine 
response, we assessed whether we could detect an infection- 
induced immune signature in the blood. Norovirus infection 
dynamically increased monocyte (Figure 3A) and neutrophil 
(Figure 3B) counts on day 2, coincident with the peak of 
proinflammatory cytokine release. A clear induction of CD40 
(Figure 4A) and HLA-DR (Figure 4D) was observed on mono-
cytes from the norovirus-infected participant a day later, on day 3. 
CD40 and HLA-DR were also upregulated on CD1c−CD304−C
D123intCD11c+ immature mDCs (Figure 4B and 4E), while only 
CD40 expression was upregulated on myeloid dendritic cells 
(CD1c+mDCs) (Figure 4C). Norovirus infection induced SIGLEC-1 
expression on CD14++CD16lo classical monocytes also peaking 
at day 3 (Figure 4F), one day after the peak of increased IFN-γ 
and IP-10 levels in the serum (Figure 2F and 2G) and prior to the 
secondary peak in sSIGLEC-1 levels in the serum (Figure 2I). 
Antigen-presenting cell populations in non-infected trial partici-
pants were quiescent following drug administration suggesting 
that the increases in CD40 and HLA-DR expression were initi-
ated by the systemic cytokine released in response to norovirus 
infection. The NK cell count peaked later in the norovirus 
infected participant on day 9 of the trial, 7 days following 
infection (Figure 5A). However, the frequency of cells express-
ing the activation marker CD69 was increased in the CD56dim 
αβTCR− (NK CD56dim, Figure 5B–5D) and NKT cell populations 
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Figure 2. Norovirus infection induces proinflammatory cytokine and sSIGLEC-1 release. (A) IL-2 levels (IU/ml) (black circles), (B) IL-
12p70 levels (pg/ml) (orange circles), (C) the percentage change in TNF-α levels from baseline (red circles), (D) IL-6 (violet circles), (E) IL-10 
(blue circles), (F) IFN-γ (pink circles), (G) IP-10 (purple circles), (H) CRP (brown circles) and (I) soluble SIGLEC-1 levels (grey circles) were 
measured in the norovirus-infected participant versus uninfected participants (green squares +/-SEM). Analytes were measured in serum or 
plasma. (B–H) Data were normalised to and expressed as percentage change from baseline (day 0). The shaded area indicates the period 
of reported gastroenteritis.
(Figure 5B, 5E and 5F) by day 3 of the trial, 1 day after infec-
tion. IL-2 administration alone had little effect on CD69 expression 
on CD56dim NK and NKT cell subsets at this dose.
Mobilisation of memory T cells by norovirus infection
Norovirus can induce Th1 immunity and generate weak memory 
responses in CD4+21 and CD8+ T cells22. However, little is known 
with regard to the dynamics of the adaptive T cell response directly 
following infection in humans. A single administration of IL-2 
dynamically affects T cells, particularly Tregs, and NK CD56bright 
cells1. However, the frequent sampling protocol of the trial 
provided enough sensitivity to distinguish the systemic response 
to infection from drug induced changes. At day 2, CD4+ central 
memory (cm) Teffs (CD4+CD45RA−CD62Lhi) and effector memory 
(em) Teffs (CD4+CD45RA−CD62Llo) decreased in frequency by 
20% and 40%, respectively, compared to smaller changes induced 
Page 6 of 20
Wellcome Open Research 2017, 2:28 Last updated: 13 JUN 2017
Figure 3. Neutrophils and monocytes are rapidly mobilised during norovirus infection. Percentage change from baseline in (A) monocyte 
and (B) neutrophil counts was determined in uninfected participants (filled green squares +/- SEM) and the norovirus-infected participant 
(filled black circles). Data were normalised to and expressed as percentage change from day 0 levels. The shaded area indicates the period 
of reported gastroenteritis.
Figure 4. Antigen presenting cells upregulate expression of costimulatory molecules and an interferon signature biomarker. 
Percentage change in CD40 expression (mean fluorescent intensity, [MFI]) from baseline was determined on (A) monocytes (CD14++), 
(B) immature myeloid DC (CD11c+ CD1c−lin− CD123intCD304−) or (C) myeloid dendritic cells (CD1c+lin−CD123−CD304−) from uninfected 
participants (filled squares +/- SEM) or the norovirus-infected participant (filled circles). Data were normalised to and expressed as percentage 
change from day 0 levels. The shaded area indicates the period of reported gastroenteritis. Inset histograms show CD40 expression at pre-
dosing (filled grey) or day 3 (red line) in the norovirus-infected participant for each cell subset. (D) Percentage change in HLA-DR expression 
(MFI) from baseline on monocytes and (E) immature myeloid DCs from uninfected participants (filled squares +/- SEM) or the norovirus-
infected participant (filled circles). Inset histograms show HLA-DR expression for each cell type at day 3 (blue line) post-IL-2 injection 
compared to pre-dosing levels (filled grey) in the norovirus-infected participant. (F) SIGLEC-1 expression (MFI) was determined on peripheral 
blood monocytes (CD14++CD16lo) in uninfected participants (filled green squares) versus the norovirus-infected participant (filled black 
circles). The shaded area indicates the period of reported gastroenteritis. All analyses were performed using cryopreserved PBMCs.
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Figure 5. Norovirus infection induces an increase in the frequency of CD69+ NK and NKT cells. The percentage change in frequency 
from baseline of total NK cells was measured using multitest TBNK tubes (A). Deeper analysis of blood NK, NKT and non-NK subsets was 
carried out using the gating strategy shown in (B). The percentage change in frequency from baseline of CD69+ CD56dim NK cells (C) and 
CD69+ NKT cells (E) was measured in uninfected participants (filled green squares +/- SEM) and the norovirus-infected participant (filled 
black circles). Data were normalised to and expressed as percentage change from baseline (day 0). Expression of CD69 and CD122 by 
αβ−TCR− CD56dim NK cells (D) and αβ+TCR+ CD56+ NKT cells (F) is shown in contour plots in the norovirus-infected participant at the indicated 
timepoints post-IL-2 administration. Histograms show the differential expression of CD69 on αβ−TCR− CD56dim NK cells (D) and αβ+TCR+ 
CD56+ NKT cells (F) at the peak of the response (day 3, blue line) versus day 0 (red line) in the norovirus-infected participant.
by IL-2 administration (Figure 6A and 6B). The behavior of 
these memory CD4+ T cell populations differed at day 3; CD4+ 
cmTeffs rebounded to a 25% increase above baseline while emT-
effs returned to baseline at day 7. In humans a large proportion of 
tissue-resident memory Teffs express CD69, a marker of T cell 
receptor-mediated signaling, which distinguishes tissue-resident 
from circulating populations23. In the circulation, CD69 expression 
is low (Figure 6D, top contour panel) and is found on a small per-
centage of mTeffs unless there is immune perturbation. In contrast 
to the drug-induced 23% increase in frequency of CD69+ cmTeffs 
at 90 minutes (Figure 6C), norovirus infection caused decreases 
of 42–62% on days 4, 7 and 9, returning toward baseline only at 
day 14. This prolonged decrease in the blood could be due to their 
homing to, and/or retention in, secondary lymphoid tissues via the 
CD62L homing receptor. A decline in frequency of cmTeffs in 
cell cycle (Ki-67+) at day 2 was also observed in the norovirus- 
infected participant (Figure 6E). However, the later recovery and 
increase in frequency of Ki-67+ cmTeffs peaking at day 4 was 
similar in the drug-treated group and the norovirus-infected 
participant. In contrast to the CD69+ cmTeff response, norovi-
rus infection doubled the proportion of CD69+ emTeffs in the 
circulation during acute gastroenteritis (day 2) (Figure 6D) and 
induced a 577% increase in frequency of Ki-67+ emTeff at day 7 
(Figure 6F).
Norovirus infection also induced dynamic changes in the CD8+ T cell 
population while IL-2 administration alone had minimal effects. 
The frequency of both CD8+ cmTeffs (CD8+CD45RA−CD62Lhi) 
and CD8+ emTeffs (CD8+CD45RA−CD62Llo) decreased at day 2 
in the blood by approximately 40%, recovering to around base-
line levels by days 4–9 (Figure 7A and 7B). Frequencies of 
CD69+CD8+ cmTeffs and CD69+CD8+ emTeffs both showed dis-
tinct peaks, ranging between 50% and 100% changes at day 3 
(Figure 7C–F). Norovirus infection also induced a 387% increase 
in frequency of Ki-67+CD8+ cmTeffs at day 4 (Figure 8A) and 
a 457% increase in Ki-67+CD8+ emTeffs at day 7 (Figure 8B). 
These data also revealed the dynamic nature of the CD8+ mTeff 
compartment itself, with one control participant showing 
increases in frequency of 662% and 1614% in Ki-67+ cmCD8+ 
Teff and Ki-67+ emCD8+ Teff, respectively, at day 9 post-treatment 
(Figure 8A and 8B).
Mouse models suggest that norovirus infection and the specific 
immune response is largely confined to the intestinal mucosa24 
and associated Peyer’s patches25. The increase in frequency 
of CD69+CD8+ Teffs suggested the release and expansion of 
tissue-resident T cells following infection. We therefore assessed 
αE (CD103) and β7 integrin expression on CD8+ mTeffs as the 
heterodimer αEβ7 is expressed on a large proportion of intestinal 
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Figure 6. Dynamic effector memory CD4+ T cell responses to norovirus infection. The percentage change in frequency of CD4+ cmTeffs 
(A), CD4+ emTeffs (B) of total CD4+ T cells from baseline levels. The percentage change in frequency of CD69+ CD4+ cmTeffs (C), CD69+ 
CD4+ emTeffs (D), Ki-67+ CD4+ cmTeffs (E) and Ki-67+ CD4+ emTeffs (F) relative to their respective baseline levels in uninfected participants 
(filled green square+/-SEM) and the norovirus-infected participant (filled black circles). The shaded area indicates the period of reported 
gastroenteritis. Contour plots showing expression of CD69 and CD25 (D) and Ki-67 and CD25 (F) on CD4+ emTeffs pre-IL-2 administration 
(day 0) and at the peak of the response in the norovirus-infected participant (day 2 or 7 respectively).
and tissue resident lymphocyte populations26. Populations of 
circulating CD8+ emTeffs (CD8+CD45RA−CD27lo) expressing 
CD103 (Figure 8C and 8D) and CD103+β7+CD8+ cmTeffs 
(CD8+CD45RA−CD27hi) (Figure 8E and 8F) were induced in the 
norovirus-infected participant to 926% and 332% above baseline 
levels, respectively, both peaking at day 7. 
Norovirus infection induces a profound counter regulatory 
response
Regulatory cells are critical to host tissue integrity during 
infection27. Despite the infection being contained within the gas-
trointestinal tract, along with the other systemic effects observed 
on innate and adaptive effector immune cell subsets, norovirus 
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Figure 7. Temporal changes in frequency and CD69 expression in memory CD8+ T cell subsets immediately following norovirus 
infection. The percentage change in frequency of CD8+ cmTeffs (A), CD8+ emTeffs (B) of total CD8+ T cells from baseline levels. The percentage 
change in frequency of CD69+ CD8+ cmTeffs (C) CD69+ emTeffs (E) relative to baseline levels in uninfected participants (filled green square+/-
SEM) and the norovirus-infected participant (filled black circles). The shaded area indicates the period of reported gastroenteritis. Contour 
plots showing expression of CD69 in the CD8+ cmTeff (D) and CD8+ emTeff (F) populations, pre-IL-2 administration (day 0) and at the peak 
of the response in the norovirus-infected participant (day 3). Histograms show the differential expression of CD69 on cmCD8+ T cells (D) and 
emCD8+ T cells (F) at the peak of the response (day 3, blue line) versus day 0 (red line) in the norovirus-infected participant.
infection induced profound phenotypic changes in the Treg 
compartment in the blood. Norovirus infection induced a 9-fold 
larger alteration in trafficking of mTregs (51% reduction) from the 
blood at day 2 compared to the control group at 90 minutes after 
drug administration (5% reduction) and the participant’s 90 minute 
post-treatment levels (13% reduction) (Figure 9A). Notably, these 
alterations broadly affected the Treg compartment, including the 
tissue homing CXCR3+ and CCR6+ mTreg subsets (Figure 9B 
and 9C). The subsequent expansion of mTregs in blood was also 
larger in the norovirus-infected participant at day 3 compared to 
the drug-induced expansion (50% versus 20% respectively) before 
returning to baseline by day 7–14. In contrast, norovirus infection 
did not increase the frequency of naïve Tregs over the observed 
IL-2-induced increase (Figure S2A). Norovirus infection induced a 
second increase of STAT5a phosphorylation in mTregs (Figure 9D 
and Figure S3A) and CD4+ mTeffs (Figure S3A) that was coinci-
dent with the release of cytokines, including IL-2, at day 2 and was 
not observed in control non-infected participants (Figure S3B). 
Norovirus infection also induced greater increases of mTreg 
CD25 (Figure 9E), FOXP3 (Figure 9F) and CTLA-4 expression 
(Figure 9G) and compared to IL-2 treatment, an effect also appar-
ent in naïve Tregs albeit at slightly lower levels (Figure S2B–D).
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Figure 8. The emergence of memory CD8+ Teffs in cell cycle and with mucosal homing capacity post-norovirus infection. The 
percentage change in frequency of Ki-67+ CD8+ cmTeffs (A) and Ki-67+ CD8+ emTeffs (B). Contour plots for each cell subset show 
Ki-67 and CD25 expression pre-IL-2 administration and at the peak of the response in the norovirus-infected participant. Timecourse 
analysis of the frequency of CD103+CD45RA−CD27− CD8+ emTeffs of total CD8+ T cells (C). Contour plots showing the frequency of 
CD103+β7integrin−/loCD45RA−CD27− CD8+ emTeffs at day 0 and day 7 post-IL-2 (D). (E) The change in frequency of CD103+β7integri
n+CD45RA−CD27+ CD8+ cmTeffs of total CD8+ T cells relative to baseline levels. (F) Contour plots showing the frequency of CD103+β7 
integrin+CD45RA−CD27+ CD8+ cmTeffs at day 0 and day 7 post-IL-2. (A, B, C and E) data were normalised to and expressed as percentage 
change from baseline (day 0) in uninfected participants (filled squares +/- SEM) or the norovirus-infected participant (filled circles). Analyses 
were performed using cryopreserved PBMCs. The shaded area indicates the period of reported gastroenteritis.
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Figure 9. A counterregulatory response to norovirus infection is coincident with effector cell mobilisation. The percentage change 
in frequency of mTregs (A), CXCR3+ mTregs (B) and CCR6+ mTregs (C) of total CD4+ T cells in the norovirus-infected and uninfected 
participants. Phosphorylation of STAT5a (MFI) in mTregs in the norovirus-infected participant and controls (filled squares +/- SD) (D). The 
percentage change in CD25 (E), FOXP3 (F) and CTLA-4 (G) expression (MFI) relative to baseline on mTregs in controls or the norovirus-
infected participant. Data were normalised to and expressed as percentage change from baseline (day 0) and measured in uninfected 
participants (filled green squares +/-SEM, n=5 apart from 9B and 9C where n=3) and the norovirus-infected (filled black circles) participant. 
The shaded area indicates the period of reported gastroenteritis. Histograms show the differential expression of CD25 (E), Foxp3 (F) and 
CTLA-4 (G) at the peak of the response (day 3: CD25, FOXP3 and day 2: CTLA-4, blue line) versus day 0 pre-IL-2 (red line) and the shaded 
grey histogram is expression of CD25, CTLA-4 and FOXP3 in naïve CD4+ Teffs at day 0 in the norovirus-infected participant, as a negative 
control for staining.
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Discussion
Frequent sampling, initially at daily intervals, revealed the broad 
and highly dynamic systemic response induced by norovirus 
infection. An acute type-1 proinflammatory cytokine release, pre-
sumably by innate lymphocytes in the gastrointestinal mucosal 
tissues, was followed by a systemic activation and mobilisa-
tion of cells of both the innate and adaptive immune systems. 
Of particular interest and novelty was the immediate and pro-
longed Treg response induced by norovirus infection. The adaptive 
clinical trial DILT1D was primarily designed to examine the 
Treg response to a single dose of IL-2 and we noted the similar-
ity between the systemic response of Tregs to the drug to that 
induced by norovirus infection. Both perturbations induced imme-
diate trafficking of Tregs followed by expansion and upregulation 
of key effector molecules, CD25, CTLA-4 and FOXP3.
The symptoms and the induction of norovirus-specific immune 
responses support norovirus as the most likely clinical cause of the 
infection in our study. However, without detection of viral RNA, 
we were unable to definitively show that norovirus was the caus-
ative organism or to identify the exact strain of norovirus in the 
infected participant. In the absence of other participants develop-
ing norovirus infection during the study we describe an n-of-1 
case study in a participant who developed the norovirus infection 
proximal to drug administration. We are confident that the five 
uninfected participants adequately controlled for the influence of 
the administration of IL-2 on the immune phenotypes induced by 
norovirus infection. Although we can not exclude the possibility 
that some of the responses that we observe were not enhanced by 
the administration of IL-2.
Similar to norovirus challenge infections10,28, the natural infec-
tion reported here transiently increased serum IFN-γ, IL-2, IL-6 
and TNF-α concentrations. The increases in TNF-α and in mono-
cyte SIGLEC-1 expression from 90 minutes onwards (in contrast 
to the five non-infected participants who received the same dose 
of IL-2 and were not infected with norovirus) are supportive of the 
norovirus infection being initiated near the time of drug admin-
istration. We also note how prolonged the sSIGLEC-1 response 
was compared to monocyte surface SIGLEC-1 expression. 
Monocyte/macrophage expression of SIGLEC-1 can be consid-
ered as a cell-specific biomarker of immunologically active cells29 
and we attribute this to prolonged activation of monocytes in the 
gut and sustained release of sSIGLEC-1. Therefore, we propose 
sSIGLEC-1 is a good candidate as a relatively long-lived marker 
of interferon release and inflammation.
Robust innate cell activation and modulation of antigen present-
ing cell populations was a feature of the cellular response fol-
lowing infection. Activation markers HLA-DR and CD40 were 
upregulated on monocytes and dendritic cell subsets one day 
after the peak of cytokine in the serum. Norovirus appears to 
actively replicate in enterocytes in vivo and in vitro30,31, rather than 
in cells of the immune system such as macrophages and dendritic 
cells32, and, as was the case with the upregulation of SIGLEC-1 
expression on monocytes, the homogeneous upregulation of these 
molecules on dendritic cells and monocytes most likely reflects a 
systemic response to systemic inflammatory cytokine release33,34. 
The frequency of CD69+CD56dimNK cells, a critical anti-viral 
effector population, acutely increased during infection, and may 
also have been activated indirectly in response to interferon 
release35. In mouse models, NKT cells are a key regulator of 
microbial homeostasis36 and could therefore have upregulated 
CD69 directly in response to norovirus in the gut. However 
cytokines, including IL-12, can also activate NKT cells and 
upregulate CD69 expression37. We therefore conclude that the 
majority of the innate cell activation signature observed in the 
blood was in response to the systemic cytokine release from 
mucosal immune cells exposed directly to the viral infection.
The increase in Treg frequency following norovirus infection 
was consistent with observations from studies of acute and 
chronic viral infections, malaria, and bacterial or fungal sepsis38–44. 
The lack of pre-infection baseline data from participants or sam-
pling close to disease diagnosis in studies of acute infection39,40,44 
appears to have precluded the identification of the trafficking of 
Tregs from the blood in response to the acute increase in cytokine 
concentrations, including IL-2. Even in a very recent study of 
the immune responses of humans to influenza vaccination, Treg 
trafficking was not reported, although they did identify a novel 
initial “lymphoid stress signature”, which they proposed requires 
further study45. Increases in serum levels of the CXCR3 ligand 
IP-10 (CXCL10) associated with IL-2 administration were much 
greater in norovirus infection and coincident with a reduction 
in frequency of CXCR3+ mTregs in the blood. CXCR3+ Tregs 
are thought to home to sites of type-1 inflammation, and IFN-γ 
signaling in Tregs promotes CXCR3+ expression and control 
of Th1 immune responses in mice46. The dramatic decline and 
increased rebound in the frequency of CCR6+ mTregs in the 
blood, and IL-10 production following norovirus infection may 
reflect the compartmentalised gastrointestinal nature of the 
infection itself4. In support of this possibility, increased serum 
CCL20 levels and an increased frequency of CCR6+ Tregs has 
been identified in patients with H. pylori47. CCR6+ mTregs 
induced by IL-2 administration or infection may traffic to mucosal 
tissues including to the gut in response to an increase in the expres-
sion of the chemokine CCL20 by the mucosa, owing to release 
of proinflammatory cytokines48,49.
Norovirus infection also induces a counter-regulatory response 
that is greater than that induced by subcutaneous IL-2 admin-
istration, with a larger expansion of Tregs that have augmented 
expression of molecules associated with increased Treg func-
tion: CTLA-4, FOXP3, CD25 and increases in serum IL-10. The 
production of IL-10, critical for mucosal integrity after norovi-
rus infection in mice50, coincides with the peaks of endogenous 
IL-2 and the proinflammatory cytokines IL-6 and IFN-γ dur-
ing acute gastroenteritis at day 2. The peak of serum cytokines 
also corresponded with a secondary peak of pSTAT5 expression 
that was predominant in Tregs that was most likely, but not 
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exclusively, induced by endogenous IL-2. Here we link the increase 
in Treg frequency and Treg CD25, CTLA-4 and FOXP3 expression 
to the infection-induced release of IL-2, detectable in the serum. 
The Treg phenotypes observed with infection were remarkably sim-
ilar to those induced by drug alone. Although norovirus infection- 
induced IL-2 levels in the blood were comparable to those observed 
at 90 minutes following IL-2 administration, we speculate that 
local IL-2 levels in the infected tissue would be considerably 
higher. Furthermore, our data are consistent with mouse models51 
illustrating a remarkable simultaneous and coordinated induction 
of regulatory and effector/inflammatory immune cell activation.
In summary, norovirus infection induces a systemic immune 
signature in the innate and adaptive immune systems. Counter- 
regulatory mechanisms are instructed early in the response to 
infection to temper collateral tissue damage, regulatory mecha-
nisms that are also induced during IL-2 therapy.
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Supplementary materials
Supplementary Figure 1. No detectable norovirus RNA in PBMC during symptomatic or asymptomatic period. (A) Real time 
RT-PCR quantification of norovirus GII standard plasmids titrated from 1×108 to 1×101 copies. (B) Real time qRT-PCR analysis of RNA 
derived from PBMC taken from all study timepoints for the infected participant +/- reverse transcriptase.
Click here to access the data.
Supplementary Figure 2. Naïve Tregs increase expression of effector molecules following norovirus infection. The percentage change 
in frequency of naive Tregs (A) of total CD4+ T cells in the norovirus-infected participant and uninfected participants from baseline levels 
(day 0). The percentage change in CD25 (B), FOXP3 (C) and CTLA-4 (D) expression (mean fluorescent intensity, [MFI]) relative to base-
line on nTregs in controls or the norovirus-infected participant. Data were normalised to and expressed as percentage change from baseline 
(day 0) and measured in uninfected participants (filled green squares +/-SEM) and the norovirus-infected (filled black circles) participant. 
The shaded area indicates the period of reported gastroenteritis.
Click here to access the data.
Supplementary Figure 3. pSTAT5a in mTregs and mTeffs in an uninfected participant and the norovirus-infected participant. 
Pseudocolour flow cytometry plots showing phosphorylation of STAT5a in CD3+CD45RA− mTeffs (FOXP3-) and mTregs (FOXP3+) in the 
norovirus-infected participant (IL-2 dose : 0.433 × 106 IU/m2) (A) and a representative uninfected participant (IL-2 dose : 0.408 × 106 IU/m2) 
(B) pre- administration (Day 0) and at the indicated timepoints post-IL-2 administration.
Click here to access the data.
Supplementary Figure 4. Figure 4A–F gating strategy.
Click here to access the data.
Supplementary Figure 5. Figures 6, 7, 8A, 8B, 9, and Supplementary Figure 2 gating strategy.
Click here to access the data.
Supplementary Figure 6. Figures 8C, 8D, 8E and 8F gating strategy.
Click here to access the data.
Supplementary Figure 7. Figure 9D gating strategy.
Click here to access the data.
Supplementary Table 1. Antibody panels used for FACS staining. Antibody clones, fluorochromes and suppliers of specific antibodies 
used for staining surface molecules on whole blood (panels 1–4), intracellular and surface molecules on whole blood (panel 5 and 6) and 
surface molecules on previously cyropreserved PBMC (panels 7–9).
Click here to access the data.
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